Current approach to connective tissue disease-associated interstitial lung disease

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 5, 2014, Pages 449-456

  Solomon, Joshua J ^a   Chartrand, Sandra ^a   Fischer, Aryeh ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

collagen vascular disease; connective tissue disease; interstitial lung disease; interstitial pneumonia; pulmonary fibrosis

Indexed keywords

AUTOANTIBODY;

COMPLICATION; CONNECTIVE TISSUE DISEASES; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOLOGY; INTERSTITIAL LUNG DISEASE;

AUTOANTIBODIES; CONNECTIVE TISSUE DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG DISEASES, INTERSTITIAL;

EID: 84906055183     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000081     Document Type: Review

References (60)

1. ATS/ERS. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors June, 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824.
3. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J 2006; 28:893-896.
4. Cottin V. Interstitial lung disease. Eur Respir Rev 2013; 22:26-32.
5. Fischer A. Interstitial lung disease: a rheumatologist's perspective. J Clin Rheumatol 2009; 15:95-99.
6. Fischer A. Interstitial lung disease in suggestive forms of connective tissue disease. J Bras Pneumol 2013; 39:641-643.
7. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012; 380:689-698.
8. Fischer A, Meehan RT, Feghali-Bostwick CA, et al. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006; 130:976-981.
9. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, et al. Antith/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006; 33:1600-1605.
10. Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012; 106:1040-1047.
11. Fischer A, Swigris JJ, du Bois RM, et al. Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. Chest 2009; 136:1072-1078.
12. Fischer A, Swigris JJ, du Bois RM, et al. Antisynthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med 2009; 103:1719-1724.
13. Fischer A, West SG, Swigris JJ, et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010; 138: 251-256.
14. Lomeo RM, Cornella RJ, Schabel SI, Silver RM. Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med 1989; 87:525-527.
15. Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J 2008; 31:11-20.
16. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012; 185:1147-1153.
17. Camus P. Drug induced infiltrative lung diseases. In: Schwarz MI, King TE, editors. Infiltrative lung diseases, 4th ed Hamilton: BC Decker, Inc; 2003. pp. 485-534.
18. Fischer A, Richeldi L. Cross-disciplinary collaboration in connective tissue disease-related lung disease. Semin Respir Crit Care Med 2014; 35: 159-165.
19. Mittoo S, Gelber AC, Christopher-Stine L, et al. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009; 103:1152-1158.
20. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther 2010; 12:213.
21. Castelino FV, Goldberg H, Dellaripa PF. The impact of rheumatological evaluation in the management of patients with interstitial lung disease. Rheumatology (Oxford) 2011; 50:489-493.
22. Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39:661-668.
23. Corrado A, Carpagnano GE, Gaudio A, et al. Nailfold capillaroscopic findings in systemic sclerosis related lung fibrosis and in idiopathic lung fibrosis. Joint Bone Spine 2010; 77:570-574.
24. Lega JC, Cottin V, Fabien N, et al. Interstitial lung disease associated with anti-PM/Scl or antiaminoacyl-tRNA synthetase autoantibodies: a similar condition? J Rheumatol 2010; 37:1000-1009.
25. Lega JC, Fabien N, Reynaud Q, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014; pii: S1568-9972(14)00101-3. doi: 10.1016/j.autrev.2014.03.004. [Epub ahead of print]
26. Bonella F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med 2014; 35:181-200.
27. Hwang JH, Misumi S, Sahin H, et al. Computed tomographic features of idiopathic fibrosing interstitial pneumonia: comparison with pulmonary fibrosis related to collagen vascular disease. J Comput Assist Tomogr 2009; 33: 410-415.
28. Lynch DA. Quantitative CT of fibrotic interstitial lung disease. Chest 2007; 131:643-644.
29. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165:1581-1586.
30. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175:705-711.
31. Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med 2007; 28:369-378.
32. Song JW, Do KH, Kim MY, et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136:23-30.
33. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003; 167:1410-1415.
34. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176:691-697.
35. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011; 140:1292-1299.
36. Ando K, Motojima S, Doi T, et al. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respir Investig 2013; 51:69-75.
37. Horai Y, Isomoto E, Koga T, et al. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol 2013; 23:190-194.
38. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20:838-844.
39. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide inthe treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41:1215-1220.
40. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37:729-735.
41. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132:947-954.
42. Steen VD, Lanz JK Jr, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37:1290-1296.
43. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666.
44. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176:1026-1034.
45. Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma- interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009; 136:1333-1340.
46. Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum 2011; 63:2797-2808.
47. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-3970.
48. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130:30-36.
49. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008; 133:455-460.
50. Koutroumpas A, Ziogas A, Alexiou I, et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010; 29: 1167-1168.
51. Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102:150-155.
52. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improveslung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40:640-646.
53. Berezne A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008; 35:1064-1072.
54. Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 2013; 107:890-896.
55. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immu-nosuppressants. Autoimmunity 2005; 38:383-392.
56. Kotani T, Takeuchi T, Makino S, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 2011; 30:1021-1028.
57. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-asso- ciated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52:2439-2446.
58. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014; 19:353-359.
59. Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54:3954-3961.
60. Saggar R, Khanna D, Furst DE, et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. Eur Respir J 2010; 36:893-900.